Solventum rises after Argus upgrades to 'buy'

Medical device maker Solventum's SOLV.N shares rise ~2.6% to $77.82

Argus Research upgrades Solventum to "buy" from "hold"

Brokerage says SOLV transformed into faster-growing and higher-margin business model

Argus raises SOLV's 2026 adjusted EPS estimate to $5.98 from $5.95

Four of 13 brokerages rate stock "buy" or higher, eight "hold" and one "sell"; their median PT is $85 - LSEG data

Including session's moves, stock up ~17.3% YTD